Bicalutamide
- Generic Name
- Bicalutamide
- Brand Names
- Casodex
- Drug Type
- Small Molecule
- Chemical Formula
- C18H14F4N2O4S
- CAS Number
- 90357-06-5
- Unique Ingredient Identifier
- A0Z3NAU9DP
- Background
Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor.
- Indication
Bicalutamide is indicated in combination with a luteinizing hormone-releasing hormone (LHRH) agonist for the treatment of Stage D2 metastatic carcinoma of the prostate.
- Associated Conditions
- Metastatic stage D2 Prostatic carcinoma
- Associated Therapies
- -
Neoadjuvant Eflornithine and Bicalutamide Compared With Eflornithine Alone, Bicalutamide Alone, and No Neoadjuvant Therapy in Treating Patients With Localized Prostate Cancer Undergoing Brachytherapy or Radical Prostatectomy
- Conditions
- Interventions
- First Posted Date
- 2004-07-12
- Last Posted Date
- 2013-11-19
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 34
- Registration Number
- NCT00086736
- Locations
- 🇺🇸
University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States
SU5416 Plus Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2004-02-06
- Last Posted Date
- 2013-09-05
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 3
- Registration Number
- NCT00026377
- Locations
- 🇺🇸
Radiation Oncology, Chicago, Illinois, United States
🇺🇸University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸LaGrange Memorial Hospital, LaGrange, Illinois, United States
Bicalutamide and Goserelin in Treating Patients With Cancer of the Ovary, Fallopian Tube, or Peritoneum
- Conditions
- First Posted Date
- 2003-11-11
- Last Posted Date
- 2013-06-18
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00012090
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Radiation Therapy With or Without Bicalutamide and Goserelin in Treating Patients With Prostate Cancer
- First Posted Date
- 2003-08-11
- Last Posted Date
- 2015-12-22
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 3
- Registration Number
- NCT00067015
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse
- First Posted Date
- 2003-03-07
- Last Posted Date
- 2023-01-18
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 413
- Registration Number
- NCT00055731
- Locations
- 🇫🇷
Centre Paul Papin, Angers, France
🇫🇷Hopital Saint Andre, Bordeaux, France
🇫🇷Institut Bergonie, Bordeaux, France
Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2020-04-03
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 361
- Registration Number
- NCT00002633
- Locations
- 🇨🇦
QEII Health Sciences Center, Halifax, Nova Scotia, Canada
🇨🇦Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
🇨🇦Cancer Centre of Southeastern Ontario at Kingston, Kingston, Ontario, Canada
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2020-10-22
- Lead Sponsor
- Radiation Therapy Oncology Group
- Target Recruit Count
- 21
- Registration Number
- NCT00030654
- Locations
- 🇺🇸
Veterans Affairs Outpatient Clinic - Martinez, Martinez, California, United States
🇺🇸Penrose Cancer Center at Penrose Hospital, Colorado Springs, Colorado, United States
🇺🇸Hope Cancer Care Center at Longmont United Hospital, Longmont, Colorado, United States
S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-07-16
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 41
- Registration Number
- NCT00028769
- Locations
- 🇺🇸
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
🇺🇸CCOP - Atlanta Regional, Atlanta, Georgia, United States
🇺🇸CCOP - Central Illinois, Decatur, Illinois, United States
Hormone Therapy in Treating Patients With Advanced Prostate Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-07-02
- Target Recruit Count
- 966
- Registration Number
- NCT00003026
- Locations
- 🇳🇱
St. Elisabeth Ziekenhuis, Tilburg, Netherlands
🇳🇱Academisch Ziekenhuis Groningen, Groningen, Netherlands
🇬🇧City General Hospital, Stoke-On-Trent, England, United Kingdom
Bicalutamide Compared With Observation Followed by Bicalutamide Plus Either Goserelin or Orchiectomy in Treating Patients With Prostate Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-09-24
- Target Recruit Count
- 110
- Registration Number
- NCT00014586
- Locations
- 🇩🇪
Center of Operative Urology Bremen, Bremen, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.